Iron Mobilization From Transferrin And Non-Transferrin-Bound-Iron by Deferiprone. Implications in the Treatment of Thalassemia, Anemia of Chronic Disease, Cancer and Other Conditions

REFERENCES

• Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassemia and other conditions. Comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003; 26(8)553–584, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sargent PJ, Farnaud S, Evans RW. Structure/function overview of proteins involved in iron storage and transport. Curr Med Chem 2005; 12(23)2683–2693, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Schlabach MR, Bates GW. The synergistic binding of anions and Fe3+ by transferrin. J Biol Chem 1975; 250(6)2182–2188, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kojima N, Bates GW. The formation of Fe3+-Transferrin-CO2−3 via the binding and oxidation of Fe2+. J Biol Chem 1981; 256(23)12034–12039, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK register. Lancet 2000; 355(9220)2051–2052, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kyriacou K, Michaelides Y, Senkus R, Simamonian K, Pavlides N, Antoniades L, Zambartas C. Ultrastructural pathology of the heart in patients with β-thalassemia major. Ultastruct Pathol 2000; 24(2)75–81, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hershko C, Bates GC, Bates BW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum fraction of potential toxicity. Br J Haematol 1978; 40(2)255–263, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Al-Refai FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in β-thalassemia patients treated with desferrioxamine and L1. Br J Haematol 1992; 82(2)431–436, [CSA]
   PubMedGoogle Scholar
• Craven CM, Alexander J, Eldridge M, Kushner JP, Bernstein S, Kaplan J. Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. Proc Natl Acad Sci USA 1987; 84(10)3457–3461, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators. Curr Med Chem 2005; 12(23)2695–2709, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Kolnagou A. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361(9352)184, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11(16)2161–2183, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Barr J, Nortey P, Sheppard L. Selection of a new generation of orally active α‐ketohydroxypyridine iron chelators intended for use in the treatment of iron overload. Am J Hematol 1993; 42(4)340–349, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. The study of iron mobilization from transferrin using α-ketohydroxy heteroaromatic chelators. Biochim Biophys Acta 1986; 869(2)141–146, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pollack S, Aisen P, Lasky FD, Vanderhoff G. Chelate mediated transfer of iron from transferrin to desferrioxamine. Br J Haematol 1976; 34(2)231–235, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Effects of ICL670 (deferasirox) on cardiac iron concentrations. Lancet 2005; 366(9488)804, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Evans RW. Site specificity of iron removal from transferrin by α-kytohydroxypyridine chelators. FEBS Lett 1985; 189(1)141–144, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Evans RW, Sharma M, Ogwang W, Patel KJ, Bartlett AN, Kontoghiorghes GJ. The effect of α-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo. Drugs Today 1992; 28(Suppl A)19–23, [CSA]
   Google Scholar
• Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharm Ther 1990; 48(3)255–261, [CSA]
   PubMed Web of Science ®Google Scholar
• Turcot I, Stintzi A, Xu J, Raymond KN. Fast biological iron chelators: kinetics of iron removal from human diferric transferrin by multidentate hydroxypyridonates. J Biol Inorg Chem 2000; 5(5)634–641, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Al-Refai FN, De Silva CE, Wonke B, Hoffbrand AV. Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload. J Clin Pathol 1995; 48(2)110–114, [CSA]
   PubMedGoogle Scholar
• Kontoghiorghes GJ, May A. Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells. Biol Metals 1990; 3(1–2)183–187, [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Forsbeck K, Nillson K, Kontoghiorghes GJ. Variation in iron accumulation, transferrin membrane binding and DNA synthesis in the K562 and U937 cell lines induced by chelators and their iron complexes. Eur J Haematol 1987; 39(4)318–325, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Blatt J, Taylor S, Kontoghiorghes GJ. Comparison of antineuroblastoma activity of desferrioxamine with that of oral iron chelators. Cancer Res 1989; 49(11)2925–2927, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Piga A, Hoffbrand AV. Cytotoxic and DNA inhibitory effects of iron chelators on human leukaemic cell lines. Haematol Oncol 1986; 4(3)195–204, [CSA]
   PubMedGoogle Scholar
• Richardson DR. Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr Med Chem 2005; 12(23)2711–2730, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Vreugdenhil G, Kontoghiorghes GJ, van Eijk HG, Swaak AJG. Impaired erythropoietin responsiveness to the anemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Exp Rheumatol 1991; 9(1)35–40, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Giordano N, Fioravanti A, Sancasciani S, Marcolongo R. Increased storage of iron and anaemia in rheumatoid arthritis: usefulness of desferrioxamine. Br Med J 1984; 289(6450)961–962, [CSA]
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Barr J, Baillod RA. Studies of aluminium mobilisation in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Arzn Forsch/Drug Res 1994; 44(4)522–526, [CSA]
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Weinberg ED. Iron: mammalian defense systems, mechanisms of disease and chelation therapy approaches. Blood Rev 1995; 9(1)33–46, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pootrakul P, Josephson B, Huebers HA, Finch CA. Quantitation of ferritin iron in plasma, an explanation for non-transferrin iron. Blood 1988; 71(4)1120–1123, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kontoghiorghes GJ. Decreased solubilisation of ferritin iron and fresh iron (III) precipitate following repeated chelator treatments. Inorg Chim Acta 1987; 138: 36–40, [CSA]
   Google Scholar